⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 3, 2024Open Access

Table S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Birgit S. Geurts Laurien J. Zeverijn Lindsay V.M. Leek Jade M. van Berge Henegouwen Louisa R. Hoes Hanneke van der Wijngaart Vincent van der Noort Joris van de Haar Annemiek van Ommen‐Nijhof Marleen Kok Paul Roepman Anne M.L. Jansen Wendy W.J. de Leng Maja J.A. de Jonge Ann Hoeben Carla M.L. van Herpen Hans M. Westgeest Lodewyk F.A. Wessels Henk M.W. Verheul Hans Gelderblom Emile E. Voest

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Table S3. Representativeness of study participants.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Geurts et al. (2024) studied this question.

synapsesocial.com/papers/68e598d9b6db643587533287 https://doi.org/10.1158/1078-0432.26926177.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol2024
2Figure S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol2024
3Data from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol2024
4Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol2024 · 4 citations
5Supplementary Figure S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer2024

More related papers

Supplementary Figure S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer2024
Supplementary Figure S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer2024
Table S4 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024